ArticleAntimicrobial resistance and infection control2020
Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011-2016) case-control study.
Article in Antimicrobial resistance and infection control, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 71 citations in OpenAlex.
- Carbapenemase-producing Enterobacterales infections: a real-world cohort study from a secondary hospital in Shanghai, China.BMC infectious diseases · 2026Article
- Risk and prognosis of infection and colonisation by carbapenemase-producingInfection prevention in practice · 2026Article
- Article
- Molecular characterization & risk factors associated with carbapenemase-producing enterobacterales acquisition in hospitalised patients in a tertiary care setting.The Indian journal of medical research · 2025Article
- Implementation of a Bundle for the Management of Patients With Gram-Negative Bloodstream Infection: A Pre-Post Quasi-experimental Study.Open forum infectious diseases · 2025Article
- Explainable AI for infection prevention and control: modeling CPE acquisition and patient outcomes in an Irish hospital with transformers.BMC medical informatics and decision making · 2025Article
- Evaluation of the NG-Test CARBA 5 for Rapid Detection of Carbapenemases in Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2025Article
- Clinical Impact of New Delhi Metallo-Beta-Lactamase-Producing Enterobacterales in Critically Ill Patients: Are We Ready to Face the Challenge?Journal of clinical medicine · 2025Article
- The evolving epidemiology of Carbapenemase-producing Enterobacterales in Canadian acute care facilities, 2010-2023.Antimicrobial resistance and infection control · 2025Article
- Community Outbreak of OXA-48-Producing Escherichia coli Linked to Food Premises, New Zealand, 2018-2022.Emerging infectious diseases · 2025Review
- Infection control interventions against carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae in an Iranian referral university hospital: A quasi-experimental study.Antimicrobial resistance and infection control · 2025Article
- Evaluating the Performance of Two Rapid Immunochromatographic Techniques for Detecting Carbapenemase in Carbapenem-ResistantInfection and drug resistance · 2025Article
- Clinical Predispositions, Features, and Outcomes of Infections with Carbapenem-resistantIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- Urinary Tract Infections with Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Risk Factors and Outcomes of Patients Colonized with KPC and NDM Carbapenemase-Producing Enterobacterales.Antibiotics (Basel, Switzerland) · 2024Article
- Epidemiology of patients harboring carbapenemase-producing bacteria and comparison with patients with detection of extended-spectrum beta-lactamase-producing Enterobacterales-A retrospective cohort study.Infection control and hospital epidemiology · 2023Article
- A Whole-Genome Sequencing-Based Approach for the Characterization ofMicroorganisms · 2023Article
- Social network and genomic analysis of an OXA-48 carbapenemase-producing Enterobacterales hospital ward outbreak in Ireland, 2018-2019.Infection prevention in practice · 2023Article
- Clonal Spread of Hospital-Acquired NDM-1-ProducingAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenemase-producing enterobacteriaceae (CPE) are a major threat for severely ill patients. However, only limited data on the epidemiology and on evidence-based infection prevention and control measures are available. The aim of this study was to investigate the epidemiology of patients with CPE, characterizing the CPE isolates by their resistance mechanisms and genetic similarity, to explore risk factors for their acquisition, and to evaluate the effectiveness of the current CPE infection control measures. Methods: A retrospective case-control study was performed using data from 2011 to 2016 in a 1800-bed academic hospital in Central Europe, where risk-based screening at patients´ admission is performed. Carbapenem resistance mechanisms of all carbapenem resistant enterobacteriaceae from patients admitted during this period were investigated. Clinical data of the CPE-positive patients were analysed and compared to a matched control group (case-control ratio of 1:3). We performed univariate and multivariate statistical analysis to identify risk factors for CPE acquisition. Results: Of 621,623 admitted patients in the study period, 75 patients with carriage of carbapenem resistant enterobacteriaceae were included (0.12/1000 admittances). Carbapenemase-encoding genes were detected in 77.3% (58/75) of patients with carbapenem-resistant enterobacteriaceae. The enzyme Conclusion: Overall, the CPE carriage rate in patients was very low, the attributable mortality, however, is alarming (53%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.